查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2072282

癲癇市場：全球市場展望、流行病學、競爭格局與市場預測報告（32個主要市場），2025-2035年

Global Epilepsy - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 156 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國癲癇市場預計將從 2025 年的 8.19 億美元成長到 2035 年的 10.7 億美元。
  • 以下因素正在推動市場成長：
  • 擴大新型抗癲癇藥物的使用
  • 擴大難治性癲癇輔助性治療的應用
  • 未來的成長取決於針對抗藥性患者的創新療法。

癲癇概述

癲癇是一種慢性神經系統疾病，其特徵是反覆發作且不可預測，由異常、過度或同步的神經元活動引起，而這些活動又是由多種結構性、遺傳性、代謝性、感染性、免疫性以及不明原因的病因造成的。國際抗癲癇聯盟（ILAE）的分類架構將癲癇發作分為局部、整體、混合性和不可預測性四種類型。其潛在機制包括興奮性和抑制性神經傳導物質失衡、離子通道功能障礙、突觸可塑性異常以及網路層面的過度興奮。遺傳性癲癇，例如Dravet症候群和KCNQ2相關性癲癇，正日益受到重視，並被認為是重要的分子疾病。患者會出現典型的陣發性症狀，包括驚厥、失神發作、局部和自動症，診斷需要至少兩次不可預測性發作或一次具有高復發風險的發作。診斷性檢查包括腦電圖（EEG），用於表徵癲癇樣活動和癲癇發作的臨床表現；磁振造影（MRI），用於識別結構性病因；以及在懷疑遺傳性癲癇時進行基因檢測。抗癲癇藥物仍然是治療的基礎，左乙拉西坦、拉莫三嗪和丙戊酸是廣泛使用的第一線藥物。拉考沙胺、布伐西坦和西諾瓦酯也是療效和耐受性良好的現代選擇。西諾瓦酯在部分性癲癇中顯示出特別高的無發作率。大麻二酚已獲準用於治療Dravet症候群和腸漏症候群。對於藥物難治性癲癇，可採用手術切除、迷走神經刺激、反應性神經刺激及深部腦部刺激等治療方法。芬氟拉明已獲準用於減少Dravet症候群的癲癇發作。三分之二癲癇發作控制的患者預後良好。駕駛限制、關於癲癇猝死風險的諮詢、心理社會支持以及以患者為中心的協作決策對於全面的長期管理至關重要。

主要亮點

  • 根據預測，德國癲癇患者總數將從 2025 年的 911,531 人增加到 2035 年的 998,705 人。
  • 癲癇仍然是全世界最常見的慢性神經系統疾病之一。
  • 雖然許多患者的癲癇發作得到了控制，但仍有相當一部分患者表現出抗藥性。
  • 人們對個人化醫療和先進的神經調控技術越來越感興趣。

市場定義：

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • 北美洲（美國、加拿大）
  • 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
  • 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
  • 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
  • 非洲（埃及、奈及利亞、南非、摩洛哥）
  • 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

大公司

  • Ono Pharmaceutical Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Shanghai UniXell Biotechnology Co., Ltd.
  • NeuroPro Therapeutics, Inc.
  • Neurelis, Inc.
  • UCB Biopharma SRL
  • Janssen Research &Development, LLC
  • UCB Pharma SA
  • Eisai Korea Inc.
  • Nova Pneuma Inc.
  • Shanghai Zhimeng Biopharma, Inc.
  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.
  • Biohaven Therapeutics Ltd.
  • Rapport Therapeutics Inc.
  • SK Life Science, Inc.
  • Suninflam Inc.
  • Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
  • NeuroPace
  • Xenon Pharmaceuticals Inc.
  • Bright Minds Biosciences Pty Ltd.
  • UCB Japan Co. Ltd.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並正在接受藥物治療的患者族群。
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 目前主要療法－概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
  • 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

  • 尚未滿足的主要需求及其透過新興療法實現的潛力。
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Global Epilepsy Market Outlook

Thelansis's "Global Epilepsy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epilepsy treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Epilepsy Overview

Epilepsy is a chronic neurological disorder defined by a predisposition to recurrent unprovoked seizures, resulting from abnormal excessive or synchronous neuronal activity arising from diverse structural, genetic, metabolic, infectious, immune, and unknown aetiologies, classified by the ILAE framework into focal, generalised, combined, and unknown onset seizure types. Underlying mechanisms encompass disrupted excitatory-inhibitory neurotransmitter balance, ion channel dysfunction, synaptic plasticity abnormalities, and network-level hyperexcitability; genetic epilepsies including Dravet syndrome and KCNQ2-related epilepsy represent increasingly recognised and therapeutically relevant molecular entities. Patients present with stereotyped paroxysmal events including convulsions, absence episodes, focal awareness impairment, and automatisms, with diagnosis requiring at least two unprovoked seizures or one seizure with high recurrence risk. Diagnostic workup integrates EEG characterising epileptiform activity and seizure semiology, MRI identifying structural aetiologies, and genetic panel testing in suspected hereditary epilepsies. Antiseizure medications remain the therapeutic cornerstone; levetiracetam, lamotrigine, and valproate are widely utilised first-line agents, with lacosamide, brivaracetam, and cenobamate representing modern options with favourable efficacy and tolerability profiles. Cenobamate has demonstrated particularly compelling seizure freedom rates in focal epilepsy. Cannabidiol is approved for Dravet syndrome and Lennox-Gastaut syndrome. Surgical resection, vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation address drug-resistant epilepsy. Fenfluramine is approved for Dravet syndrome seizure reduction. Prognosis is favourable in two-thirds of patients achieving seizure control; driving restrictions, SUDEP risk counselling, psychosocial support, and patient-centred shared decision-making are integral to comprehensive long-term management.

Key Highlight

  • In Germany, total prevalent epilepsy cases are projected to increase from 911,531 in 2025 to 998,705 by 2035.
  • Epilepsy remains one of the most common chronic neurological disorders worldwide.
  • While many patients achieve seizure control, a significant proportion remain drug-resistant.
  • Growing focus on personalized treatment and advanced neuromodulation technologies.

Market Overview

  • The France epilepsy market is projected to grow from $819M in 2025 to $1.07B by 2035.
  • Market growth is supported by:
  • Increased utilization of newer anti-seizure medications
  • Growing adoption of adjunctive therapies for refractory epilepsy
  • Future growth will depend on innovative therapies targeting drug-resistant populations.

Market Definition:

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

  • Ono Pharmaceutical Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • Shanghai UniXell Biotechnology Co., Ltd.
  • NeuroPro Therapeutics, Inc.
  • Neurelis, Inc.
  • UCB Biopharma SRL
  • Janssen Research & Development, LLC
  • UCB Pharma SA
  • Eisai Korea Inc.
  • Nova Pneuma Inc.
  • Shanghai Zhimeng Biopharma, Inc.
  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.
  • Biohaven Therapeutics Ltd.
  • Rapport Therapeutics Inc.
  • SK Life Science, Inc.
  • Suninflam Inc.
  • Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
  • NeuroPace
  • Xenon Pharmaceuticals Inc.
  • Bright Minds Biosciences Pty Ltd.
  • UCB Japan Co. Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)